Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This automated IHC assay has been analytically verified and validated using Dako’s autostainer Link 48 and 22C3 mouse anti-PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Roach, Charlotte, Zhang, Nancy, Corigliano, Ellie, Jansson, Malinka, Toland, Grant, Ponto, Gary, Dolled-Filhart, Marisa, Emancipator, Kenneth, Stanforth, Dave, Kulangara, Karina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957959/
https://www.ncbi.nlm.nih.gov/pubmed/27333219
http://dx.doi.org/10.1097/PAI.0000000000000408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957959/
https://www.ncbi.nlm.nih.gov/pubmed/27333219
http://dx.doi.org/10.1097/PAI.0000000000000408

Ejemplares similares